Amyris - AMRS Stock Forecast, Price & News

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Amyris Stock Performance

AMRS Stock opened at $3.55 on Friday. The firm has a market cap of $1.14 billion, a PE ratio of -2.35 and a beta of 1.62. Amyris has a 12-month low of $1.47 and a 12-month high of $16.31. The company has a quick ratio of 1.13, a current ratio of 1.66 and a debt-to-equity ratio of 1.26. The business has a 50 day moving average of $2.20 and a 200-day moving average of $3.24.

Amyris (NASDAQ:AMRS - Get Rating) last announced its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The firm had revenue of $65.20 million during the quarter, compared to analysts' expectations of $81.53 million. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.16) EPS. As a group, sell-side analysts expect that Amyris will post -1.11 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on AMRS shares. JPMorgan Chase & Co. assumed coverage on Amyris in a report on Friday, June 24th. They issued a "neutral" rating for the company. Piper Sandler started coverage on shares of Amyris in a research report on Wednesday, May 25th. They set a "neutral" rating and a $2.50 price target on the stock. Finally, Roth Capital downgraded shares of Amyris from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 10th.

Insider Buying and Selling

In other Amyris news, CEO John Melo sold 55,576 shares of Amyris stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $2.12, for a total value of $117,821.12. Following the transaction, the chief executive officer now directly owns 492,701 shares of the company's stock, valued at approximately $1,044,526.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO John Melo sold 55,576 shares of the business's stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $2.12, for a total value of $117,821.12. Following the sale, the chief executive officer now directly owns 492,701 shares of the company's stock, valued at approximately $1,044,526.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Nicole Kelsey sold 94,033 shares of the firm's stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $1.80, for a total transaction of $169,259.40. Following the sale, the insider now owns 63,333 shares of the company's stock, valued at $113,999.40. The disclosure for this sale can be found here. Insiders sold 199,225 shares of company stock worth $403,182 in the last quarter. 33.80% of the stock is owned by insiders.